EMEA-002598-PIP01-19

Key facts

Active substance
Fexapotide (friflutate)
Therapeutic area
Uro-nephrology
Decision number
P/0346/2019
PIP number
EMEA-002598-PIP01-19
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of benign prostatic hyperplasia
Route(s) of administration
Intraprostatic use
Contact for public enquiries
FGK Representative Service GmbH

E-mail: info@nymox.com
Tel. +1 8009369669

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating